statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference PR Newswire SAN DIEGO, May 7...

Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal...

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating...

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

Neurocrine Biosciences Presented CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024 Neurocrine Biosciences Presented CAHtalyst Pediatric Study Baseline...

Neurocrine Biosciences Presented CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024

Latest Ratings for NBIX
 DateFirmActionFromTo Mar 2022Piper SandlerDowngradesOverweightNeutral Feb 2022Goldman SachsUpgradesNeutralBuy Feb 2022Morgan StanleyMaintainsEqual-Weight
 View More...

Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences

Neurocrine Biosciences Reports First Quarter 2024 Financial Results Neurocrine Biosciences Reports First Quarter 2024 Financial Results PR Newswire SAN DIEGO, May 1, 2024 INGREZZA (valbenazine) First...

Neurocrine Biosciences Reports First Quarter 2024 Financial Results

Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules PR...

Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major...

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial...

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results

Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder Neurocrine Biosciences Announces First-Patient Dosed in...

Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Watchers	3,064
52-Wk Low	$89.04
52-Wk High	$148.37

Volume	667,258.00
52-Wk High	$148.37
52-Wk Low	$89.04

NBIX Neurocrine Biosciences, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals